@article{cbbc4cbec27d4a71a2c78803ac2133bf,
title = "Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study",
author = "Noriko Fukuhara and Go Yamamoto and Hideki Tsujimura and Takaaki Chou and Hirohiko Shibayama and Tomoko Yanai and Kazunori Shibuya and Koji Izutsu",
note = "Funding Information: This study was supported by Takeda Pharmaceutical Company Ltd. The authors thank all of the patients who participated in this study. The authors are grateful to the following investigators who participated to this study and provided data; Yoshiki Akatsuka (Fujita Health University School of Medicine, Toyoake), Hideki Asaoku (Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima), Hideki Goto (Hokkaido University Faculty of Medicine, Graduate School of Medicine, Sapporo), Hitoshi Hanamoto (Kindai University Nara Hospital, Ikoma), Shigeki Ito (Iwate Medical University School of Medicine, Morioka), Manabu Kawakami (Nippon Life Hospital, Osaka), Toshio Kitawaki (Graduate School of Medicine, Kyoto University, Kyoto), Yuichi Mori (Saku Central Hospital, Saku), Akihito Shinohara (Tokyo Women's Medical University, Tokyo), Taizo Shimomura (Kumamoto Shinto General Hospital, Kumamoto), Takayuki Shimizu (Keio University School of Medicine, Tokyo), Jun Taguchi (Shizuoka Red Cross Hospital, Shizuoka), Satoshi Yamamoto (Sapporo City General Hospital, Sapporo), Masahiro Yokoyama (The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo), Toshiyuki Yokoyama (Sendai Medical Center, Sendai), and Kanako Yoshitsugu (Shizuoka Cancer Center, Shizuoka). Funding Information: N. Fukuhara reports grants from Ono Pharmaceutical Co. Ltd., during the conduct of the study. G. Yamamoto reports grants from Takeda Pharmaceutical Co. Ltd., during the conduct of the study; personal fees from Takeda Pharmaceutical Co. Ltd., outside of the submitted work. H. Shibayama reports research funding from Takeda, during the conduct of the study; personal fees from Takeda, Novartis, Celgene, Janssen, Chugai, Eisai, Mundi Pharma, Ono, Otsuka, Kyowa Hakko Kirin, AstraZeneca, Abbvie, Dainippon Sumitomo, Daiichi Sankyo, Fujimoto, Nihon Shinnyaku, Sanofi, and Bristol, outside of the submitted work. ",
year = "2020",
month = jan,
day = "2",
doi = "10.1080/10428194.2019.1654100",
language = "English",
volume = "61",
pages = "176--180",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",
}
